Irdi Soridec leads €16m funding round for Advicenne

Advicenne plans to use the funding to further develop its nephrology and neurology treatment projects, including a study of an orphan renal tubulopathy disease, which has currently no known treatment options.

Existing investors BPI France and Ixo Private Equity also took part in this latest funding round.

Previous funding
In May 2011, BPI France led a €5.1m round for Advicenne alongside Ixo.

Company
Advicenne is a late-stage pharmaceutical company developing paediatric drugs for treating neurological diseases. The company was founded in 2007 and headquartered in Nimes. 

People
Advicenne – Luc-André Granier (CEO).
Irdi Soridec Gestion – Jean-Michel Petit (investment manager).
BPI France – Philippe Boucheron (deputy head of life sciences investments).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• BPI France
• iXO Private Equity
• L'IRDI
• Venture